ImmunityBio says ANKTIVA plus BCG met main goal in BCG-naive bladder cancer trial
IBRX•ImmunityBio said ANKTIVA plus BCG met the primary endpoint in its randomized QUILT-2.005 trial in BCG-naive non-muscle-invasive bladder cancer, with no treatment-related deaths reported. The company said a supplemental BLA for ANKTIVA remains on track for submission to the FDA by year-end 2026.
1. Trial results
ImmunityBio said ANKTIVA plus BCG met the primary endpoint in its randomized QUILT-2.005 trial in BCG-naive non-muscle-invasive bladder cancer. The company reported no treatment-related deaths and said a supplemental BLA for ANKTIVA is on track for FDA submission by year-end 2026.
